Integrating imaging and clinical trials to drive scalable healthcare growth

Resonance Health Ltd (ASX: RHT) has emerged as a compelling case study in corporate reinvention, transitioning from a niche medical imaging specialist to a diversified healthcare technology and clinical trials services provider. The company’s recent financial results and strategic initiatives underscore its potential to capitalise on structural tailwinds in the global clinical trials market, which is projected to grow at a 7.2% compound annual rate to $887 billion by 2032. With record cash receipts of $13.1 million over the 12 months to December 2024—a 143% year-on-year increase—and a transformed business model encompassing three synergistic divisions, Resonance Health offers investors exposure to a high-growth sector through a platform built on recurring revenue streams, regulatory expertise, and technological innovation.

From Single Product to Integrated Clinical Trials Partner

Resonance Health’s strategic pivot since FY2021 has seen the company evolve into three complementary business units:

• Software-as-Medical Device (SaMD): Generating $2.6 million in 1HFY25 revenue (36% of group total), this division provides AIenhanced MRI analysis for liver iron, fat, and cardiac iron quantification. Flagship products like FerriScan® (global gold standard for liver iron measurement) and CardiacT2* have achieved regulatory clearance in major markets
• Contract Research Organisation (CRO) Services: Contributing $3.1 million (43% of revenue), this segment manages end-to-end clinical trials, having secured $20.1 million in major pharma contracts since August 2023, including a $13.8 million 24-month agreement signed in November 2024.
• TrialsWest Investigator Sites: Acquired in 2024, this business contributed $1.5 million (21% of revenue) from two Perth sites, with a third location planned for 2HFY25 to support patient recruitment for CRO trials

The integration of these units creates a vertically aligned offering—from trial design (CRO) to participant recruitment (TrialsWest) to biomarker analysis (SaMD)—reducing sponsor coordination costs while improving data integrity. This structural advantage is reflected in intersegment revenue of $0.6 million during 1HFY25, demonstrating operational synergies.

Financial Performance and Capital Management

Accelerating Top-Line Growth The company delivered record 1HFY25 results, with key metrics illustrating both scale and efficiency improvements:

Notably, the last twelve months to December 2024 saw cash receipts of $13.1 million—exceeding the cumulative total from FY2021–FY2023—demonstrating the step-change from recent contract wins. The balance sheet remains robust with $3.5 million cash against $3.0 million debt, yielding a net cash position of $0.5 million. Free cash flow conversion stood at 166% of normalised EBITDA, suggesting sustainable self-funding capacity for growth initiatives.

Growth Catalysts and Operational Execution

Near-Term Value Drivers:

1. CRO Contract Backlog: $13.3 million remains to be invoiced across active trials, providing 24-month revenue visibility. The November 2024 contract alone represents 265% of FY2024 CRO revenue
2. SaMD Automation: Deployment of AI-driven tools increased report generation capacity by 40% in 1HFY25 trials, critical for scaling high-margin services
3. Site Expansion: TrialsWest’s third site (planned Q3 FY25) triples participant capacity, directly supporting CRO contract delivery while creating standalone revenue potential
4. Pipeline Products: The Extended Proof-of-Concept (EPOC) trial for non-invasive MRI Liver Fibrosis analysis—a $32 billion TAM opportunity—is progressing with additional data collection sites coming online in 2HFY25.

Addressing Investor Concerns

While Resonance Health exhibits strong momentum, prudent analysis requires acknowledging key risks:

1. Customer Concentration: Two major pharma contracts account for 85% of CRO’s $20.1 million backlog. However, diversification is emerging through TrialsWest’s blue-chip sponsors (AstraZeneca, Novartis, Sanofi) and SaMD’s 300+ clinical trial partnerships
2. Regulatory Hurdles: As a Class II/III medical device developer, FDA/EU MDR approvals for pipeline products (e.g., Liver Fibrosis SaMD) could face delays. The company mitigates this through early commercialisation under investigational use protocols
3. Integration Risk: TrialsWest’s acquisition added $3.2 million in deferred consideration payments. However, the business has exceeded EBITDA targets since integration, suggesting successful execution.

Competitively, Resonance Health’s ISO 13485 certification and proprietary algorithms (protected by 12 patents) create barriers to entry in quantitative MRI analysis—a sector growing at 8.4% annually. The CRO division’s focus on metabolic/liver trials aligns with global R&D priorities, as 34% of Phase III pipeline drugs target these conditions.

Strategic Outlook and Capital Allocation

Management’s capital discipline is evident in three areas:

1. Debt Management: The $3.2 million NAB facility (3.2% margin over BBSW) funds TrialsWest expansion while maintaining conservative leverage (0.5x Net Debt/EBITDA)
2. R&D Investment: $1.2 million annualised spend focused on automation and pipeline products, yielding 15% efficiency gains in 1HFY25
3. M&A Strategy: Active pursuit of accretive acquisitions in clinical trial ancillary services (e.g., central labs, ePRO platforms) to deepen ecosystem integration.

The company’s “land and expand” strategy—using SaMD/CRO credibility to cross-sell TrialsWest services—has already increased average revenue per sponsor by 22% since FY2023. With the Australian clinical trial market growing at 4.1% CAGR (vs. 3.2% GDP), Resonance Health’s addressable market could exceed $120 million domestically by FY2027.

Resonance Health’s transformation into a vertically integrated healthcare technology and clinical trials provider has delivered strong financial growth, operational synergies, and a robust platform for future expansion. With record revenue and cash flow, a diversified business model and a growing contract backlog, the company is well-positioned to capitalise on global clinical trial market tailwinds. While customer concentration and regulatory risks remain, management’s disciplined execution and strategic focus on recurring revenue streams and innovation support a positive outlook for long-term value creation.

Disclaimer | | This document has been prepared by the Sales, Trading and Investment Advisory department and not by a Research department. Liquidity Technology Pty Ltd seeks to and does business with companies covered in its research reports. Thus, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this as only a single factor in making their investment decisions. The company featured in this document should be considered speculative in nature and carry a high degree of investment risk. Please consider if investments in these types of companies are appropriate for your personal circumstance.

This document accurately expresses the personal view of the Author at the time of writing. Liquidity Technology Pty, Corporate Authorised Representative (CAR: 001293556) of Mac Equity Partners Pty Ltd (AFSL 338731, ABN 32 126 369 640), its directors, associates and employees advise that they may hold securities, may have an interest in and/or earn brokerage and other benefits or advantages, either directly or indirectly from client transactions arising from any advice mentioned in publications to clients. Directors, associates and employees of Liquidity Technology Pty Ltd from time to time may hold shares in the security/securities mentioned in this Research document and, therefore, may benefit from any increase in the price of those securities. This research note has been prepared for and is intended for Wholesale Investors only as defined by Section 761G of the Corporations Act, 2001. In accordance with Section 949A of the Corporations Act 2001, this document contains unsolicited general financial information only. In preparing this document Liquidity Technology Pty Ltd did not consider the investment objectives, financial situation and particular needs (‘financial circumstances’) of any particular person and no recommendation (whether express or implied) contained in this document should be considered reliable. Accordingly, before acting on any information contained in this document, you should assess whether the information is appropriate in light of your own financial circumstances or contact your Liquidity Technology Pty Ltd adviser. Liquidity Technology Pty Ltd believe that the information herein is accurate however no warranty of accuracy or reliability is given in relation to any information or information contained in this publication and no responsibility for any loss or damage whatsoever arising in any way for any representation, act or omission, whether express or implied (including responsibility to any persons by reason of negligence), is accepted by Liquidity Technology Pty Ltd or any officer, agent or employee of Liquidity Technology Pty Ltd.

© 2025. No part of this report may be reproduced or distributed in any manner without permission of Liquidity Technology Pty Ltd.